Heart failure: metabolic derangements and therapeutic rationale

References

• American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. American Heart Association TX, USA (2005).
   Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation112, 154–235 (2005).
   PubMed Web of Science ®Google Scholar
• Damas JK, Gullestad L, Aukrust P. Cytokines as new treatment targets in chronic heart failure. Curr. Control Trials Cardiovasc. Med.2, 271–277 (2001).
   PubMedGoogle Scholar
• Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J. Am. Coll. Cardiol.26, 1565–1564. (1995).
   PubMed Web of Science ®Google Scholar
• Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann. Intern. Med.117, 502–510 (1992).
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail. Rev.7, 149–159 (2002).
   PubMedGoogle Scholar
• Fonarow GC. An approach to heart failure and diabetes mellitus. Am. J. Cardiol.96(4), 47–52 (2005).
   PubMed Web of Science ®Google Scholar
• Tansey MJ, Opie LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet2, 419–22 (1983).
   PubMed Web of Science ®Google Scholar
• Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation104, 2923–2931 (2001).
   PubMed Web of Science ®Google Scholar
• Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeyer H. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation106, 407–411 (2002).
   PubMedGoogle Scholar
• Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation108, 1552–1553 (2003).
   PubMed Web of Science ®Google Scholar
• Yang LL, Gros R, Kabir MG et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation109(2), 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol.91, 30H–37H (2003).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J. Clin. Endocrinol. Metab.88, 516–523 (2003).
   PubMed Web of Science ®Google Scholar
• Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiac myocyte apoptosis. J. Cell. Physiol.189(3), 257–265 (2001).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Udelson JE, Anand IS et al. Ventricular remodeling in HF: a credible surrogate endpoint. J. Card. Fail.9, 350–353 (2003).
   PubMed Web of Science ®Google Scholar
• Vignola PA, Aonuma K, Swaye PS et al. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J. Am. Coll. Cardiol.4, 812–819 (1984).
   PubMed Web of Science ®Google Scholar
• Stevenson WG, Stevenson LW. Prevention of sudden death in HF. J. Cardiovasc. Electrophysiol.12, 112–114 (2001).
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group, Effect of metoprolol CR/XL in chronic heart failure: the MEtoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Mahdyoon H, Klein R, Eyler W, Lakier JB, Chakko SC, Gheorghiade M. Radiographic pulmonary congestion in endstage congestive heart failure. Am. J. Cardiol.63, 625–627 (1989).
   PubMed Web of Science ®Google Scholar
• Mccullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of HF: analysis from Breating Not Properly (BNP) multinational study. Circulation106, 416–422 (2002).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of HF. N. Engl. J. Med.347, 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Maisel A. B-type natriuretic peptide levels: a potential novel ‘white count’ for congestive heart failure. J. Card. Fail.7, 183–193 (2001).
   PubMed Web of Science ®Google Scholar
• Maisel AS, McCullough PA. Cardiac natriuretic peptides:a proteomic window to cardiac function and clinical management. Rev. Cardiovasc. Med.4(Suppl. 4), S3–S12 (2003).
   Google Scholar
• Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA guidelines for coronary artery bypass graft surgery. J. Am. Coll. Cardiol.34, 1262–1347 (1999).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Jacober SJ, Winer N et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care25, 718–723 (2002).
   PubMed Web of Science ®Google Scholar
• Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J. Am. Coll. Cardiol.41, 56–61 (2003).
   PubMed Web of Science ®Google Scholar
• Majumder SR, McAlister FM, Soumerai S. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am. J. Med.115, 467–472 (2003).
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Chen YT, Wang Y et al. Predictors of readmission among elderly survivors of admission with HF. Am. Heart J.139, 72–77 (2000).
   PubMed Web of Science ®Google Scholar
• Baker DW. Prevention of heart failure. J. Card. Fail.8, 333–346 (2002).
   PubMed Web of Science ®Google Scholar
• Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation105, 1727–1733 (2002).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular & microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Wang CH, Weisel RD, Liu PP et al. Glitazones and HF: critical appraisal for the clinician. Circulation107, 1350–1354 (2003).
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Pedersen TR, Olsson AG et al. The effects of simvastatin on the incidence of HF in patients with coronary heart disease. J. Card. Fail.3, 249–254 (1997).
   PubMedGoogle Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Lampert R, Ickovics JR, Viscoli CJ et al. Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the β-blocker heart attack trial. Am. J. Cardiol.91, 137–142 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med.327, 669–677(1992).
   PubMed Web of Science ®Google Scholar
• Hebert PR, Gaziano JM, Chan KS et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA278, 313–321 (1997).
   PubMed Web of Science ®Google Scholar
• Allen Maycock CA, Muhlestein JB, Horne BD et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J. Am. Coll. Cardiol.40, 1777–1785 (2002).
   PubMed Web of Science ®Google Scholar
• Guerci AD, Gerstenblith G, Brinker JA et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med.317, 1613–1618 (1987).
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with HF. N. Engl. J. Med.336, 525–533 (1997).
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Heart failure in diabetic patients: utility of β-blockade. J. Card. Fail.9, 333–344 (2003).
   PubMed Web of Science ®Google Scholar
• Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med.347, 1403–1411 (2002).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet362, 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by HF, left ventricular dysfunction, or both. N. Engl. J. Med.349, 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J.148, 122–128 (2004).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet362, 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med.314(24), 1547–1552 (1986).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med.325(5), 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med.351, 2049–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe HF. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.348, 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• DiMarco JP. Implantable cardioverter-defibrillators. N. Engl. J. Med.349, 1836–1847 (2003).
   PubMed Web of Science ®Google Scholar
• Kuhlkamp V: InSync 7272 ICD World Wide Investigators. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J. Am. Coll. Cardiol.39, 790–797 (2002).
   PubMed Web of Science ®Google Scholar
• Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann. Intern. Med.141, 343–351 (2004).
   PubMed Web of Science ®Google Scholar
• Cleland G, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352, 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Yu CM, Abraham WT, Bax J et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)–study design. Am. Heart J.149, 600–605 (2005).
   PubMed Web of Science ®Google Scholar
• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J.26, 1115–1140 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold JM, Liu P, Demers C et al. Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can. J. Cardiol.22, 23–45 (2006).
   PubMed Web of Science ®Google Scholar
• Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail.12, 10–38 (2006).
   PubMed Web of Science ®Google Scholar
• Urbanek K, Rota M, Cascapera S et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res.87, 663–673 (2005).
   Google Scholar
• Massie BM, Force T. The year in heart failure 2005. J. Card. Fail.12, 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial, Lancet364, 141–148 (2004).
   PubMed Web of Science ®Google Scholar
• Schachinger V. Intracoronary infusion of bone marrow-derived progenitor cells in acute myocardial infarction: a randomized, double-blind, placebo-controlled multicenter trial (REPAIR-AMI). Late-breaking clinical trial. Presented at: American Heart Association Annual Scientific Session. Dallas, TX, USA, 13–16 November (2005).
   Google Scholar
• Lunde K. The effects on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction: the ASTAMI Randomized Controlled Trial. Late-breaking clinical trial. Presented at: American Heart Association Annual Scientific Session. Dallas, TX, USA, 13–16 November (2005).
   Google Scholar
• McNamara D. The A-HeFT pharmacogenomic analysis. Late-breaking trial. Presented at: Heart Failure Society of America Annual Meeting. Boca Raton, FL, USA, 18–21 September (2005).
   Google Scholar